Analyst Ratings For ConvaTec (LON:CTEC)
Today, Goldman Sachs Group lowered its price target on ConvaTec (LON:CTEC) to GBX 118 per share.
There are 5 Hold Ratings, 5 Buy Ratings, 2 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on ConvaTec (LON:CTEC) is Hold with a consensus target price of GBX 179.42 per share, a potential .
Some recent analyst ratings include
- 2/18/2019-ConvaTec (LON:CTEC) had its Neutral rating reiterated by JPMorgan Chase & Co. with a GBX 135 price target
- 2/14/2019-ConvaTec (LON:CTEC) had its Hold rating reiterated by Peel Hunt with a GBX 150 price target
- 1/21/2019-ConvaTec (LON:CTEC) had its Buy rating reiterated by Numis Securities with a GBX 220 price target
About ConvaTec (LON:CTEC)
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as for traumatic injury, burns, invasive surgery, and other causes. The company also provides a portfolio of wound dressings that include antimicrobial and foam dressings to manage chronic wounds comprising pressure, venous leg, and diabetic foot ulcers. In addition, it offers devices, accessories, and services consisting of Esteem+ one-piece and Natura+ two-piece advanced pouch ranges for people with an ostomy or stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. Further, the company provides continence and critical care products, including intermittent urinary catheters; advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and a range of disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, and gastroenterology tubes. Additionally, it offers disposable infusion sets to the suppliers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and a range of products to hospitals and the home healthcare sector. The company markets its products through internal sales force, distributors, wholesalers, hospitals, specialist medical stores, pharmacies, and homecare agencies. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 2008 and is headquartered in Reading, the United Kingdom.
Recent Trading Activity for ConvaTec (LON:CTEC)
Shares of ConvaTec closed the previous trading session at 120,40 −1,05 0,86 % with shares trading hands.
